Latest Audit News

NeuroScientific Biopharmaceuticals achieved an 80% clinical response rate in fistulising Crohn’s disease patients treated under the TGA Special Access Scheme, advancing plans for Phase 2 trials and manufacturing scale-up.

Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.

Whitehaven Coal delivered a robust finish to FY26, hitting top-end guidance for production and sales while improving safety and reducing costs.

St Barbara Limited has increased its 15-Mile Processing Hub Mineral Resources Estimate by 20%, now totaling 2.5 million ounces of gold, driven by updated geological models and integration of extensive historical drilling data.

WT Financial Group reports a 20% rise in net profit before tax for FY2026, underpinned by its scalable adviser network and strategic Hubco platform expansion.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

The Star Entertainment Group reported a significant improvement in quarterly EBITDA loss alongside stable revenue, completing key joint venture exit and refinancing milestones that boosted liquidity to $267 million.

Key Petroleum Limited continued its push for Potential Commercial Area approvals for ATP 920 and ATP 924 while completing two share placements that bolstered its working capital. The company remains focused on securing tenure certainty and expanding its asset portfolio amid measured financial management.

MaxiPARTS upgrades FY26 operating profit guidance to $14.2 million, driven by strong cost control and a $9 million inventory reduction, while bolstering its executive team with key appointments.

Genetic Signatures has completed a major restructure delivering $5 million in annual savings from FY2027 and secured a decade-long supply contract with Denmark’s Hvidovre Hospital, while posting $14.8 million revenue for FY2026 amid market pressures.

Credit Clear Limited has posted a 28% revenue increase to $60 million and a 41% jump in underlying EBITDA to $10.4 million for FY26, beating guidance and driven by organic growth and recent acquisitions in Europe and debt collection.

Alcidion delivered a record Q4 FY26 operating cashflow of $7.7 million and secured a $35 million UK contract, while completing a strategic acquisition that expands its ANZ footprint.